Aerovate Therapeutics, Inc. (NASDAQ: AVTE - Get Free Report) dropped 0.5% during mid-day trading on Friday. The company traded as low as $12.30 and last traded at $12.48. Approximately 136,019 shares were traded during mid-day trading, an increase of 994% from the average daily volume of 12,438 shares. The stock had previously closed at $12.54.

Volatility and Risk Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Earnings and Valuation This table compares Aerovate Therapeutics and Graybug Vision"s

Squarepoint Ops LLC bought a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,564 shares of the company’s stock, valued at approximately $52,000. Squarepoint Ops LLC owned approximately 0.07% of Aerovate Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other institutional investors and hedge funds have also made changes to their positions in AVTE. Braidwell LP bought a new stake in shares of Aerovate Therapeutics during the fourth quarter valued at approximately $3,817,000. ADAR1 Capital Management LLC boosted its stake in shares of Aerovate Therapeutics by 720.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company’s stock worth $2,459,000 after acquiring an additional 814,941 shares during the last quarter. Allostery Investments LP purchased a new position in shares of Aerovate Therapeutics during the 4th quarter valued at $2,254,000. Affinity Asset Advisors LLC lifted its stake in shares of Aerovate Therapeutics by 33.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company’s stock valued at $2,120,000 after buying an additional 200,000 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Aerovate Therapeutics in the 4th quarter valued at $1,590,000. Aerovate Therapeutics Stock Performance Shares of NASDAQ AVTE opened at $7.71 on Wednesday. The company has a market cap of $223.47 million, a P/E ratio of -2.58 and a beta of 0.95. The firm’s fifty day moving average is $40.11 and its two-hundred day moving average is $71.98. Aerovate Therapeutics, Inc. has a 52-week low of $43.75 and a 52-week high of $884.98. Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) last posted its earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($10.50) by $7.35. As a group, analysts forecast that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year. Aerovate Therapeutics Announces Dividend The company also recently declared a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were paid a dividend of $84.00 per share. The ex-dividend date of this dividend was Tuesday, April 29th. Aerovate Therapeutics Profile (Free Report) Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 The combined company will operate as “Jade Biosciences, Inc.” and will trade on Nasdaq under the ticker symbol “JBIO” SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. (“Aerovate”). The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on April 29, 2025, under the ticker symbol “JBIO.

—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass. , April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger.

Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass. , April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement").

Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass. , April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Aerovate Therapeutics, Inc. (NasdaqGM: AVTE) and Jade Biosciences. Pursuant to the terms of the agreement, shareholders of Aerovate will own approximately 1.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the m.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences. Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity.